Sprycell
(Dasatinib)
(100 mg)
(thirty)
(Tablets)
Sprycel (dasatinib) 100 mg 30 tabs or 50 mg 60 tabs BRISTOL, Germany
Article:
In Stock
Indications:
- Chronic myeloid leukemia (CML) in the accelerated or blast phase with resistance or intolerance to previous therapy, which included imatinib mesylate.
- Acute lymphoblastic leukemia with a positive Philadelphia chromosome (Ph + ALL), as well as lymphoblastic form of chronic myeloid leukemia (CML) with resistance or intolerance to previous therapy.185/225/380
-
Commercial name:Sprycell
-
Сhemical name:Dasatinib
-
Dosage:100 mg
-
Quantity:thirty
-
Release form:Tablets
No reviews yet